Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ENV-501 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ENV-501, a putative antibody-drug conjugate (ADC) targeting ERBB3 (HER3) (May 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ENV-501 | ENV 501|ENV501 | HER3 (ERBB3) Antibody 28 | Limited information is currently available on ENV-501, a putative antibody-drug conjugate (ADC) targeting ERBB3 (HER3) (May 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06956690 | Phase Ib/II | ENV-501 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Recruiting | USA | AUS | 0 |